Dr. Faus’ early years of scientific research focused on the regulation of gene expression at the transcriptional level. He was an EMBO (European Molecular Biology Organization) fellow at the CNRS-Bristol Myers Squibb Research Center in Strasbourg (France), and later set up his own research group at the Howard Hughes Medical Institute at the University of Chicago (USA). After a career in academic research he transitioned to industry, where he held positions in several pharmaceutical companies. In 2006 Dr. Faus was one of the founders of Palau Pharma, a Barcelona-based biotech company focused on developing new drugs for the treatment of autoimmune and inflammation-based pathologies. The company raised 48 M € in several venture-backed financing rounds and executed a myriad of licensing agreements with global pharmaceutical companies. He successfully divested the company in 2013, selling its assets to some of the largest global pharmaceutical companies in the world. The laboratories and personnel of Palau Pharma were integrated in the structure of the LEITAT Technology Park as a new Drug Discovery & Development company, Draconis Pharma. Dr. Faus received a Ph.D. in Biochemistry from Indiana University (USA) and an MBA from the Kellogg Graduate School of Management, Northwestern University (USA). He also holds a PDG from IESE (Barcelona)

 Medicine,Biochemistry